IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9066954 B1

PDFFull Text
Date of Patent:
Jun. 30, 2015

Filed:

Jun. 13, 2013

Fused heterocyclic derivatives and methods of use

Applicant:

Amgen Inc., Thousand Oaks, CA (US);

Inventors:

Brian K. Albrecht, Cambridge, MA (US);

David Bauer, Sudbury, MA (US);

Steven Bellon, Wellesley, MA (US);

Christiane M. Bode, Somerville, MA (US);

Shon Booker, Thousand Oaks, CA (US);

Alessandro Boezio, Somerville, MA (US);

Deborah Choquette, Medford, MA (US);

Derin D'Amico, Newbury Park, CA (US);

Jean-Christophe Harmange, Andover, MA (US);

Satoko Hirai, Brookline, MA (US);

Randall W. Hungate, Camarillo, CA (US);

Tae-Seong Kim, Thousand Oaks, CA (US);

Richard T. Lewis, Farmingham, MA (US);

Longbin Liu, Thousand Oaks, CA (US);

Julia W. Lohman, San Francisco, CA (US);

Mark H. Norman, Thousand Oaks, CA (US);

Michele Potashman, Cambridge, MA (US);

Aaron C. Siegmund, Ventura, CA (US);

Stephanie K. Springer, Cambridge, MA (US);

Markian Stec, Moorpark, CA (US);

Ning Xi, Thousand Oaks, CA (US);

Kevin Yang, San Gabriel, CA (US);

Assignee:

Amgen Inc., Thousand Oaks, CA (US);

Attorney:

Olga Mekhovich

Primary Examiner:

Venkataraman Balasubramanian

Int. Cl.
CPC ...
C07D 487/04 (2006.01); C07D 403/12 (2006.01); A61K 31/4192 (2006.01); A61K 31/4353 (2006.01); A61K 31/4709 (2006.01); A61P 35/00 (2006.01); A61K 31/538 (2006.01); C07D 471/04 (2006.01); C07D 493/04 (2006.01); C07D 495/04 (2006.01); C07D 498/04 (2006.01); C07D 519/00 (2006.01); A61K 31/437 (2006.01); A61K 31/497 (2006.01); A61K 31/5025 (2006.01); A61K 31/506 (2006.01); A61K 31/52 (2006.01); A61K 31/5377 (2006.01); A61K 45/06 (2006.01); C07D 473/34 (2006.01);
U.S. Cl.
CPC ...
A61K 31/538 (2013.01); C07D 403/12 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07D 493/04 (2013.01); C07D 495/04 (2013.01); C07D 498/04 (2013.01); C07D 519/00 (2013.01); A61K 31/437 (2013.01); A61K 31/497 (2013.01); A61K 31/5025 (2013.01); A61K 31/506 (2013.01); A61K 31/52 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); C07D 473/34 (2013.01);
Abstract

Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

Find Patent Forward Citations

Loading…